Person who experienced the adverse event (patient)
Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
127024521 | 12702452 | 1 | I | 20160611 | 20160831 | 20160831 | PER | US-JNJFOC-20160611009 | JANSSEN | 0.00 | A | M | Y | 182.00000 | KG | 20160831 | OT | US | US |
Drug(s) used by person
Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
127024521 | 12702452 | 1 | SS | STELARA | USTEKINUMAB | 1 | Subcutaneous | N | N | UNKNOWN | 0 | 45 | MG | SOLUTION FOR INJECTION | |||||
127024521 | 12702452 | 2 | SS | STELARA | USTEKINUMAB | 1 | Subcutaneous | N | N | UNKNOWN | 0 | 45 | MG | SOLUTION FOR INJECTION | |||||
127024521 | 12702452 | 3 | PS | STELARA | USTEKINUMAB | 1 | Subcutaneous | N | N | UNKNOWN | 125261 | 45 | MG | SOLUTION FOR INJECTION | /month | ||||
127024521 | 12702452 | 4 | C | VICTOZA | LIRAGLUTIDE | 1 | Unknown | 0 | 1.8 | MG | UNSPECIFIED | QD | |||||||
127024521 | 12702452 | 5 | C | LANTUS | INSULIN GLARGINE | 1 | Unknown | 70 UNITS | 0 | UNSPECIFIED | |||||||||
127024521 | 12702452 | 6 | C | NOVOLOG | INSULIN ASPART | 1 | Unknown | SLIDING DOSE | 0 | UNSPECIFIED | |||||||||
127024521 | 12702452 | 7 | C | METFORMIN | METFORMIN HYDROCHLORIDE | 1 | Unknown | 0 | 500 | MG | UNSPECIFIED | BID | |||||||
127024521 | 12702452 | 8 | C | LISINOPRIL. | LISINOPRIL | 1 | Unknown | 0 | 2.5 | MG | UNSPECIFIED | QD | |||||||
127024521 | 12702452 | 9 | C | METHOTREXATE. | METHOTREXATE | 1 | Unknown | 0 | 6 | DF | UNSPECIFIED | QD | |||||||
127024521 | 12702452 | 10 | C | GABAPENTIN. | GABAPENTIN | 1 | Unknown | 0 | 600 | MG | UNSPECIFIED | TID |
Indications of drugs used
Event ID | CASEID | INDI DRUG SEQ | INDI PT |
---|---|---|---|
127024521 | 12702452 | 1 | Psoriatic arthropathy |
127024521 | 12702452 | 2 | Psoriatic arthropathy |
127024521 | 12702452 | 3 | Psoriatic arthropathy |
127024521 | 12702452 | 4 | Type 2 diabetes mellitus |
127024521 | 12702452 | 5 | Type 2 diabetes mellitus |
127024521 | 12702452 | 6 | Type 2 diabetes mellitus |
127024521 | 12702452 | 7 | Type 2 diabetes mellitus |
127024521 | 12702452 | 8 | Type 2 diabetes mellitus |
127024521 | 12702452 | 9 | Psoriatic arthropathy |
127024521 | 12702452 | 10 | Neuropathy peripheral |
Outcome of event
no results found |
Reactions reported
Event ID | CASEID | DRUG REC ACT | PT |
---|---|---|---|
127024521 | 12702452 | Fatigue | |
127024521 | 12702452 | Feeling jittery | |
127024521 | 12702452 | Inappropriate schedule of drug administration |
Reporting Sources (this data is often not reported and may therefore be missing here)
no results found |
Therapies reported
Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
---|---|---|---|---|---|---|
127024521 | 12702452 | 1 | 20150211 | 2016 | 0 | |
127024521 | 12702452 | 2 | 201606 | 0 | ||
127024521 | 12702452 | 3 | 2016 | 201606 | 0 |